BHC Healthcare

Bausch Health Companies Inc.

$8.14+1.50%

Price as of close on Nov 3, 2026 · Financials updated Nov 1, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Canada
Market cap: 3.0B USD
Enterprise value: 21.3B USD
Full-time employees: 20,300

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.44 vs a peer median of 2.59)higher risk: less liquidity (current ratio 1.44 vs peers 2.59)
About average: valuation

Ranks #903 of 1,157 healthcare companies (bottom 23%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
Bausch Health Companies's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Earnings slid into a loss. Loss per share this year after a profit last year.
Bausch Health Companies made a loss per share in its latest year after a profit the year before.
Valuation signals disagree. Cheaper than 79% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 79% of peers on operating cash profit, but only 0% on earnings.
Relative to its operating cash profit (EBITDA), Bausch Health Companies looks cheaper than 79% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, Bausch Health Companies looks cheaper than 79% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Loss over 12 months, profit last quarter. Lost money in the 12 months to June 2026, but made a $258M profit in the quarter to June 2026.
Bausch Health Companies reported a net loss over the last twelve months, but its most recent quarter was profitable ($258M). One quarter isn't a trend, but it's closer to profitability than the 12-month figure suggests.

StockQuotient Score

35/ 100

Oct 5 35 → Nov 4 35

Valuation

Is the price right?

56/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Mixed versus peers:

▲ EBITDA yield
▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-36.1%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield9.4%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score 1.34Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield47.0%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingOutlier capped at sector 5th/95th percentile20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-58.2%

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

36/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 3.1%

Why

Weaker than most peers on:

▼ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a profit to a loss33% base weight · Z-score -1.99Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth9.1%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 0.39Sector median: 0.0584 · MAD: 0.0840

Revenue growth10.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.41Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

39/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 2.6 points to 8.1%

Why

Weaker than most peers on:

▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin8.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.09Sector median: 0.0706 · MAD: 0.1217

Return on assets-4.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.14Sector median: 0.0166 · MAD: 0.0537

Return on invested capital4.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.06Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin72.6%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-11040.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.37

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.75Sector median: 0.6250 · MAD: 0.3380

Current ratio1.44×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.83Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Bausch Health Companies

Is Bausch Health Companies getting weaker?: Its latest SEC filing (Jul 30, 2026) got stronger: operating margin rose 2.6 points to 8.1%. Its overall score is unchanged at 35/100 since Oct 28, 2026.
How is Bausch Health Companies valued vs its peers?: Priced about in line with its peers. Valuation scores 56/100 against 1,393 healthcare peers. EBITDA yield 9.4% vs a peer median of 4.0% (stronger than 79% of peers).EBITDA yield 9.4% vs peers 4.0% (stronger than 79% of peers). Earnings yield -36.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -36.1% vs peers 1.5% (weaker than 100% of peers).
Is Bausch Health Companies growing?: More slowly than most of its peers. Growth scores 36/100 against 1,393 healthcare peers. Revenue growth 10.1% vs a peer median of 6.1% (stronger than 61% of peers).Revenue growth 10.1% vs peers 6.1% (stronger than 61% of peers).
How profitable is Bausch Health Companies?: Less profitable than most of its peers. Profitability scores 39/100 against 1,393 healthcare peers. Return on assets -4.4% vs a peer median of 1.7% (weaker than 69% of peers).Return on assets -4.4% vs peers 1.7% (weaker than 69% of peers).
How risky is Bausch Health Companies?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.37 vs a peer median of 0.63 (stronger than 72% of peers).Beta 0.37 vs peers 0.63 (stronger than 72% of peers). Current ratio 1.44× vs a peer median of 2.59× (weaker than 76% of peers).Current ratio 1.44× vs peers 2.59× (weaker than 76% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 30, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Operating margin rose 2.6 points to 8.1%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	10.5B USD	10.9B USD	+3.1%
Net income (12 months)	−1.2B USD	−1.1B USD	−9.1%
Operating margin	5.6%	8.1%	+2.6 pts
Free cash flow (12 months)	1.0B USD	1.4B USD	+39.2%
Debt	20.8B USD	20.7B USD	−0.1%
Cash	1.3B USD	1.8B USD	+40.5%
Shares outstanding	373.5M	374.0M	+0.1%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	5.3%	5.6%	11.0%	16.1%	17.7%	▲ 1.6 pts
Net margin	-11.2%	-2.8%	-6.8%	-0.5%	1.5%	▲ 2.0 pts
Return on assets (ROA)	-3.2%	-0.9%	-2.2%	-0.2%	0.6%	▲ 0.8 pts
Free cash flow margin	13.7%	-11.6%	9.3%	13.1%	9.8%	▼ 3.3 pts
Current ratio	1.08×	1.08×	1.30×	0.86×	1.47×	▲ 72%
Quick ratio	0.89×	0.80×	0.94×	0.62×	1.08×	▲ 75%
Interest coverage	0.32×	0.31×	0.73×	1.11×	1.13×	▲ 1.5%

BHC price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.44 vs a peer median of 2.59)higher risk: less liquidity (current ratio 1.44 vs peers 2.59)

About average: valuation

Ranks #903 of 1,157 healthcare companies (bottom 23%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

Bausch Health Companies's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Earnings slid into a loss. Loss per share this year after a profit last year.

Bausch Health Companies made a loss per share in its latest year after a profit the year before.

Valuation signals disagree. Cheaper than 79% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 79% of peers on operating cash profit, but only 0% on earnings.

Relative to its operating cash profit (EBITDA), Bausch Health Companies looks cheaper than 79% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, Bausch Health Companies looks cheaper than 79% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Loss over 12 months, profit last quarter. Lost money in the 12 months to June 2026, but made a $258M profit in the quarter to June 2026.

Bausch Health Companies reported a net loss over the last twelve months, but its most recent quarter was profitable ($258M). One quarter isn't a trend, but it's closer to profitability than the 12-month figure suggests.

Questions investors ask about Bausch Health Companies

Is Bausch Health Companies getting weaker?

Its latest SEC filing (Jul 30, 2026) got stronger: operating margin rose 2.6 points to 8.1%. Its overall score is unchanged at 35/100 since Oct 28, 2026.

How is Bausch Health Companies valued vs its peers?

Priced about in line with its peers. Valuation scores 56/100 against 1,393 healthcare peers. EBITDA yield 9.4% vs a peer median of 4.0% (stronger than 79% of peers).EBITDA yield 9.4% vs peers 4.0% (stronger than 79% of peers). Earnings yield -36.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -36.1% vs peers 1.5% (weaker than 100% of peers).

Is Bausch Health Companies growing?

More slowly than most of its peers. Growth scores 36/100 against 1,393 healthcare peers. Revenue growth 10.1% vs a peer median of 6.1% (stronger than 61% of peers).Revenue growth 10.1% vs peers 6.1% (stronger than 61% of peers).

How profitable is Bausch Health Companies?

Less profitable than most of its peers. Profitability scores 39/100 against 1,393 healthcare peers. Return on assets -4.4% vs a peer median of 1.7% (weaker than 69% of peers).Return on assets -4.4% vs peers 1.7% (weaker than 69% of peers).

How risky is Bausch Health Companies?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.37 vs a peer median of 0.63 (stronger than 72% of peers).Beta 0.37 vs peers 0.63 (stronger than 72% of peers). Current ratio 1.44× vs a peer median of 2.59× (weaker than 76% of peers).Current ratio 1.44× vs peers 2.59× (weaker than 76% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

10.5B USD

10.9B USD

+3.1%

Net income (12 months)

−1.2B USD

−1.1B USD

−9.1%

Operating margin

5.6%

8.1%

+2.6 pts

Free cash flow (12 months)

1.0B USD

1.4B USD

+39.2%

Debt

20.8B USD

20.7B USD

−0.1%

Cash

1.3B USD

1.8B USD

+40.5%

Shares outstanding

373.5M

374.0M

+0.1%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

5.3%

5.6%

11.0%

16.1%

17.7%

▲ 1.6 pts

Net margin

-11.2%

-2.8%

-6.8%

-0.5%

1.5%

▲ 2.0 pts

Return on assets (ROA)

-3.2%

-0.9%

-2.2%

-0.2%

0.6%

▲ 0.8 pts

Free cash flow margin

13.7%

-11.6%

9.3%

13.1%

9.8%

▼ 3.3 pts

Current ratio

1.08×

1.30×

0.86×

1.47×

▲ 72%

Quick ratio

0.89×

0.80×

0.94×

0.62×

1.08×

▲ 75%

Interest coverage

0.32×

0.31×

0.73×

1.11×

1.13×

▲ 1.5%